What is Travere Therapeutics, Inc.'s R&D?

Travere Therapeutics, Inc. (TVTX) reported R&D of $57.09M in Q1 2026.

How has Travere Therapeutics, Inc.'s R&D changed year-over-year?

Travere Therapeutics, Inc.'s R&D increased by 21.8% year-over-year, from $46.89M to $57.09M.

What is the long-term trend for Travere Therapeutics, Inc.'s R&D?

Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s R&D has grown at a 0.6% compound annual growth rate (CAGR), from $201.16M to $206.01M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Travere Therapeutics, Inc. TVTX R&D

R&D at other companies

LQD

Liquidia CorporationLQDA

$12.57M+80.5%

BridgeBio PharmaBBIO

$126.64M+13.6%

Arrowhead ResearchARWR

$173.25M+30.2%

PTC TherapeuticsPTCT

$100.87M-7.4%

Scholar RockSRRK

$51.81M+6.4%

Protagonist TherapeuticsPTGX

$46.74M+30.2%

Segments

By segment

See full

Reportable Segment$57.09M+21.8%

Other financials

Income statement

See full

Revenue$127.2M+55.6%

Gross profit$125.2M+62.5%

Operating income-$36.9M+13.5%

Net income-$37.1M+10.0%

EPS (diluted)-$0.40+14.9%

Balance sheet

See full

Cash & equivalents$78.4M+26.6%

Total debt$15.6M-82.6%

Total equity$98.7M+201%

Total assets$555.2M+1.2%

Cash flow

See full

Operating cash flow-$40.4M+4.3%

CapEx$140.0K—

Free cash flow-$42.5M+28.1%

Valuation

See full

Market cap$5.13B+72.3%

Enterprise value$5.07B+65.5%

P/S9.6×-1.3×

Profitability

See full

Gross margin98.6%+2.6pp

Operating margin-10.6%-5.0pp

Net margin-20.3%-9.5pp

FCF margin-133.9%-34.4pp

Returns & leverage

See full

Return on equity-706%-1,302pp

Debt / equity0.2×-2.6×

Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Travere Therapeutics, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Travere Therapeutics, Inc.'s R&D?: Travere Therapeutics, Inc. (TVTX) reported R&D of $57.09M in Q1 2026.
How has Travere Therapeutics, Inc.'s R&D changed year-over-year?: Travere Therapeutics, Inc.'s R&D increased by 21.8% year-over-year, from $46.89M to $57.09M.
What is the long-term trend for Travere Therapeutics, Inc.'s R&D?: Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s R&D has grown at a 0.6% compound annual growth rate (CAGR), from $201.16M to $206.01M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.